Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Source:
bloombergMarkets
June 24, 2026 · 12:52
Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on patient eligibility. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)
The original article opens on the publisher's website.
More from General
View topic →Japanese green tea giant Ito En surges 8%, defying a broad market sell-off
cnbc
Sep 1, 2026 · 19:24
Australia posts second-quarter growth of 2.1%, beating expectations
cnbc
Sep 1, 2026 · 18:47
Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group
bbcTechnology
Sep 1, 2026 · 18:27
Massachusetts’ 80-year-old senator sees off primary challenge over his age
financialTimes
Sep 1, 2026 · 18:06
Pentagon chaos deepens after Driscoll quits in clash with Hegseth
financialTimes
Sep 1, 2026 · 17:47